Apimeds Pharmaceuticals (APUS) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing Apitox, a bee venom-based biologic for osteoarthritis (OA) and multiple sclerosis (MS).

• Holds exclusive U.S. rights to Apitox via a sublicensable, royalty-bearing license from Apimeds Korea.

• Apitox is not yet FDA-approved; prior clinical success in South Korea but U.S. approval requires further Phase III trials.

• Business strategy focuses on advancing Apitox for advanced knee OA and exploring MS indications through non-registered studies.

• Plans to outsource manufacturing and leverage trade secrets for process protection.

Financial performance and metrics

• No revenue generated to date; operations funded by equity and convertible notes.

• Net loss of $1,078,357 for the nine months ended September 30, 2024; net loss of $777,694 for the year ended December 31, 2023.

• Accumulated deficit of $4,080,291 as of September 30, 2024.

• Cash balance of $26,571 as of September 30, 2024; pro forma as adjusted cash post-offering estimated at $8.8 million.

• Auditor's report includes a going concern explanatory paragraph due to recurring losses and limited cash runway.

Use of proceeds and capital allocation

• Estimated net proceeds of $8.8 million (up to $10.2 million with full over-allotment) at $3.00 per share.

• Proceeds allocated to fund Phase III knee OA trial (~$6.5M), initiate MS studies (~$1M), manufacturing (~$1M), repay short-term debt, and for working capital.

• Any remaining funds may be used for strategic investments or acquisitions.